DOCSLIB.ORG

FDA-IDSA-NIH-Pew Public Workshop: November 21St 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FDA-IDSA-NIH-Pew Public Workshop: November 21St 2019 Meeting November 19, 2019 Page 1 1 FOOD AND DRUG ADMINISTRATION 2 ________________________________ 3 FDA-IDSA-NIH-Pew Public Workshop 4 Enhancing the Clinical Trial Enterprise for 5 Antibacterial Drug Development in the United States 6 ________________________________ 7 8 DATE: Day 1: November 18, 2019 9 TIME: 8:30 a.m. 10 LOCATION: FDA White Oak Campus 11 10903 New Hampshire Avenue 12 Building 31 Great Room 13 Silver Spring, MD 20993 14 REPORTED BY: Michael Farkas, Notary Public 15 JOB No.: 3472551 16 17 18 19 20 21 22 23 www.CapitalReportingCompany.com 202-857-3376 Meeting November 19, 2019 Page 2 1 PARTICIPANTS: 2 3 JOHN FARLEY 4 AARON DANE 5 ROGER LEWIS 6 DAVID MELNICK 7 RIENK PYPSTRA 8 CHIBUZOR UCHEA 9 VANCE FOWLER 10 CYNTHIA SEARS 11 SARA COSGROVE 12 REBECCA REINDEL 13 LINDSEY BADEN 14 WES KIM 15 JOHN REX 16 HELEN BOUCHER 17 SUMATHI NAMBIAR 18 ERIN DUFFY 19 AMANDA JEZEK 20 KEVIN OUTTERSON 21 JANE KNISELY 22 DENNIS DIXON 23 www.CapitalReportingCompany.com 202-857-3376 Meeting November 19, 2019 Page 3 1 MARK ALBRECHT 2 AMY LEITMAN 3 NICK KARTSONIS 4 RYAN CIRZ 5 SUE CAMMARATA 6 MANOS PERROS 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 www.CapitalReportingCompany.com 202-857-3376 Meeting November 19, 2019 Page 4 1 P R O C E E D I N G S 2 JOHN FARLEY: So good morning, 3 everybody. I'm John Farley. I'm the Acting Director 4 of what is now called the Office of Infectious 5 Diseases at the Center for Drugs here at FDA. We want 6 to welcome you to this workshop. 7 Next slide, please. 8 So I thought we might go ahead and 9 start the morning by focusing on why we're all here. 10 This is -- should look familiar to those of you who 11 have taken a look at the recent CDC AMR threats 12 report. We've had some progress from stewardship 13 efforts, but the serious public health challenge 14 continues with 2.8 million antibiotic resistant 15 infections each year and 35,000 deaths. 16 How about this? Okay. I will lean 17 forward. 18 So I want to begin the day by just 19 thanking Ed Cox for his leadership here at the agency. 20 As most of you are aware, he left government service 21 after nearly two decades, and really a steady hand and 22 focus on science and the data on his part played a key 23 www.CapitalReportingCompany.com 202-857-3376 Meeting November 19, 2019 Page 5 1 role in the progress over the last decade, making safe 2 and effective new antibacterial drugs available for 3 patients in the setting of AMR. 4 I also want to take a moment to thank 5 everybody who is sitting in this room for your 6 steadfast commitment, your innovation, your positive 7 dialogue, and your collaboration in the midst of what 8 has been a decade of scientific and economic 9 challenges. 10 So we at the agency really appreciate 11 your commitment. Cindy -- I was telling Cindy Sears 12 earlier, I come from the world of perinatal HIV where 13 I felt like we built a strong collaborative 14 partnership over time and there were major 15 accomplishments. And I feel like the dynamic is the 16 same here, and it's really an honor for those of us in 17 the agency to be part of that. 18 I thought we'd begin today by just 19 doing some brief introductions, and your disclosures 20 are already listed in the program, so you don't have 21 to provide any voluntary disclosures as you introduce 22 yourself. But maybe we'll start with Aaron and move 23 www.CapitalReportingCompany.com 202-857-3376 Meeting November 19, 2019 Page 6 1 around the table from there. 2 AARON DANE: I'm Aaron Dane. I'm a 3 statistical consultant who's been working in the area 4 of infectious diseases for about 20 years. 5 ROGER LEWIS: Good morning. I'm Roger 6 Lewis. I'm the Chair of Emergency Medicine at Harbor- 7 UCLA Medical Center and the Senior Medical Scientist 8 at Berry Consultants where I focus on adaptive and 9 innovative clinical trial design. 10 DAVID MELNICK: I'm David Melnick, the 11 Chief Medical Officer at Spero Therapeutics, a small 12 biotech based in Cambridge, Massachusetts. We have 13 three active programs in the antibacterial space. 14 RIENK PYPSTRA: Hi, I'm Rienk Pypstra. 15 I'm head of development for the hospital business unit 16 in Pfizer; hospital business unit includes all the 17 antibiotics. I have also some years of experience 18 with developing antibiotics. 19 CHIBUZOR UCHEA: Good morning, 20 everybody. My name is Chibuzor Uchea. I'm a science 21 officer in the Drug Resistant Infections Program at 22 the Wellcome Trust. We are working on a range of 23 www.CapitalReportingCompany.com 202-857-3376 Meeting November 19, 2019 Page 7 1 different interventions in the AMR space to lead the 2 program about combatting antimicrobial resistance in a 3 range of different areas. And I'll be speaking later 4 on in tomorrow's session on the use of clinical trial 5 networks. 6 VANCE FOWLER: Good morning. I'm Vance 7 Fowler. I'm the Contact Principal Investigator for 8 the Antibacterial Resistance Leadership Group and the 9 Chair of the Infectious Disease Society Antimicrobial 10 Resistance Committee. 11 CYNTHIA SEARS: Good morning. I'm 12 Cindy Sears. I'm past President of IDSA and Professor 13 of Medicine at Johns Hopkins, and I'm an infectious 14 diseases physician. 15 SARA COSGROVE: Good morning. My name 16 is Sara Cosgrove. I'm a Professor of Medicine at 17 Johns Hopkins also and also in the Division of 18 Infectious Diseases, and I am the Medical Director of 19 our Department of Antimicrobial Stewardship. 20 REBECCA REINDEL: I'm Rebecca Reindel. 21 I'm a pediatric infectious disease physician by 22 training. I'm a Medical Officer in the Office of 23 www.CapitalReportingCompany.com 202-857-3376 Meeting November 19, 2019 Page 8 1 Vaccines in CBER. 2 LINDSEY BADEN: Lindsey Baden. I'm a 3 Physician Investigator at Brigham & Women's Dana 4 Farber, and an Editor with the "New England Journal of 5 Medicine" focusing on infectious diseases. 6 WES KIM: Good morning, Wes Kim with 7 Pew Charitable Trusts. I'm the Senior Officer of our 8 innovation workstream our Antibiotic Resistance 9 Project. 10 JOHN REX: I'm John Rex. I'm an 11 internist trained in infectious diseases. I am 12 currently the Chief Medical Officer of a company, a 13 private company that has an antifungal in phase two, 14 so not specifically a topic for this for today. And 15 also, I work for Wellcome Trust as their advisor for 16 their investment strategy and drug resistant 17 infections. 18 HELEN BOUCHER: Good morning. I'm 19 Helen Boucher from Tufts Medical Center in Boston, 20 where I practice infectious diseases and I'm the 21 Treasurer of IDSA. 22 SUMANTHI NAMBIAR: Good morning. I'm 23 www.CapitalReportingCompany.com 202-857-3376 Meeting November 19, 2019 Page 9 1 Sumanthi Nambiar, Director Division of Anti- 2 Infectives. 3 ERIN DUFFY: Good morning. My name is 4 Erin Duffy. I'm the Chief of R&D of CARB-X. We're 5 going to talk about CARB-X later today. But briefly, 6 we're a global partnership that funds and accelerates 7 innovation and antibiotic drug discovery. 8 AMANDA JEZEK: Hi, I'm Amanda Jezek 9 with IDSA. I'm our Senior Vice President for Public 10 Policy and Government Relations. 11 KEVIN OUTTERSON: Kevin Outterson. I 12 might be the only lawyer around the table. I'm a law 13 professor at Boston University, and I'm the Principal 14 Investigator of CARB-X. 15 JANE KNISELY: Good morning, Jane 16 Knisely. I am with the National Institutes of Health, 17 National Institute of Allergy & Infectious Diseases. 18 DENNIS DIXON: Good morning, everybody. 19 I'm Dennis Kixon, also from National Institute of 20 Allergy & Infectious Diseases at NIH. I'm Chief of 21 the Bacteriology and Mycology Branch. We manage all 22 of the escape pathogens. And I've had a chance to 23 www.CapitalReportingCompany.com 202-857-3376 Meeting November 19, 2019 Page 10 1 observe these challenging areas for nearly three 2 decades at NIH as we've developed various mechanisms 3 to shore up our defenses and had prior experience in 4 academia, political lab, and briefly in industry. 5 MARK ALBRECHT: Good morning, everyone. 6 My name is Mark Albrecht. I am the Chief of the 7 Antibacterials Branch at BARDA. 8 AMY LEITMAN: Good morning. My name is 9 Amy Leitman. I'm the Director of Policy and Research 10 at a patient advocacy group called NTM Info and 11 Research. We advocate on behalf of patients with 12 pulmonary nontuberculous micro bacterial disease, 13 bronchiectasis and other gram-negative pathogens. 14 NICK KARTSONIS: Good morning. My name 15 is Nick Kartsonis. I'm an infectious disease 16 physician, and I currently provide oversight for 17 infectious disease and vaccines at Merck Research Labs 18 at Merck & Co., Inc. 19 RYAN CIRZ: And good morning. My name 20 is Ryan Cirz. I'm currently an independent 21 consultant.
Load more

Recommended publications
  • Pharmaceutical and Veterinary Compounds and Metabolites
    PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES High quality reference materials for analytical testing of pharmaceutical and veterinary compounds and metabolites. lgcstandards.com/drehrenstorfer [email protected] LGC Quality | ISO 17034 | ISO/IEC 17025 | ISO 9001 PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES What you need to know Pharmaceutical and veterinary medicines are essential for To facilitate the fair trade of food, and to ensure a consistent human and animal welfare, but their use can leave residues and evidence-based approach to consumer protection across in both the food chain and the environment. In a 2019 survey the globe, the Codex Alimentarius Commission (“Codex”) was of EU member states, the European Food Safety Authority established in 1963. Codex is a joint agency of the FAO (Food (EFSA) found that the number one food safety concern was and Agriculture Office of the United Nations) and the WHO the misuse of antibiotics, hormones and steroids in farm (World Health Organisation). It is responsible for producing animals. This is, in part, related to the issue of growing antibiotic and maintaining the Codex Alimentarius: a compendium of resistance in humans as a result of their potential overuse in standards, guidelines and codes of practice relating to food animals. This level of concern and increasing awareness of safety. The legal framework for the authorisation, distribution the risks associated with veterinary residues entering the food and control of Veterinary Medicinal Products (VMPs) varies chain has led to many regulatory bodies increasing surveillance from country to country, but certain common principles activities for pharmaceutical and veterinary residues in food and apply which are described in the Codex guidelines.
    [Show full text]
  • Treatment Processes for Microbial Resistance Mitigation: the Technological Contribution to Tackle the Problem of Antibiotic Resistance
    International Journal of Environmental Research and Public Health Review Treatment Processes for Microbial Resistance Mitigation: The Technological Contribution to Tackle the Problem of Antibiotic Resistance Gabriela Bairán 1, Georgette Rebollar-Pérez 2, Edith Chávez-Bravo 1,* and Eduardo Torres 1,* 1 Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico; [email protected] 2 Facultad de Ingeniería Química, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico; [email protected] * Correspondence: [email protected] (E.C.-B.); [email protected] (E.T.) Received: 24 September 2020; Accepted: 24 November 2020; Published: 28 November 2020 Abstract: Advances generated in medicine, science, and technology have contributed to a better quality of life in recent years; however, antimicrobial resistance has also benefited from these advances, creating various environmental and health problems. Several determinants may explain the problem of antimicrobial resistance, such as wastewater treatment plants that represent a powerful agent for the promotion of antibiotic-resistant bacteria (ARB) and antibiotic resistance genes (ARG), and are an important factor in mitigating the problem. This article focuses on reviewing current technologies for ARB and ARG removal treatments, which include disinfection, constructed wetlands, advanced oxidation processes (AOP), anaerobic, aerobic, or combined treatments, and nanomaterial-based treatments. Some of these technologies are highly intensive, such as AOP; however, other technologies require long treatment times or high doses of oxidizing agents. From this review, it can be concluded that treatment technologies must be significantly enhanced before the environmental and heath problems associated with antimicrobial resistance can be effectively solved.
    [Show full text]
  • ( 12 ) United States Patent ( 10 ) Patent No .: US 10,835,538 B2 Averback ( 45 ) Date of Patent : Nov
    US010835538B2 ( 12 ) United States Patent ( 10 ) Patent No .: US 10,835,538 B2 Averback ( 45 ) Date of Patent : Nov. 17 , 2020 ( 54 ) METHOD OF TREATING BENIGN 7,241,738 B2 7/2007 Averback et al . 7,317,077 B2 1/2008 Averback et al . PROSTATIC HYPERLASIA WITH 7,408,021 B2 8/2008 Averback et al . ANTIBIOTICS 7,745,572 B2 6/2010 Averback et al . 8,067,378 B2 11/2011 Averback et al . ( 71 ) Applicant: Nymox Corporation , Nassau ( BS ) 8,293,703 B2 10/2012 Averback et al . 8,569,446 B2 10/2013 Averback et al . 8,716,247 B2 5/2014 Averback et al . ( 72 ) Inventor : Paul Averback , Nassau ( BS ) 2016/0215031 Al 7/2016 Averback 2016/0361380 A1 12/2016 Averback ( 73 ) Assignee : NYMOX CORPORATION , Nassau 2017/0020957 Al 1/2017 Averback ( BS ) 2017/0360885 Al 12/2017 Averback 2018/0064785 Al 3/2018 Averback ( * ) Notice : Subject to any disclaimer , the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154 ( b ) by 21 days. WO 90/08555 A1 8/1990 WO WO - 2007149312 A2 * 12/2007 A61K 8/606 ( 21 ) Appl. No .: 15 /938,920 ( 22 ) Filed : Mar. 28 , 2018 OTHER PUBLICATIONS McClellan et al. , Topical Metronidazole A Review of its Use in ( 65 ) Prior Publication Data Rosacea, 2000 , Am J Clin Dermatol, 1 ( 3 ) , pp . 191-199 ( Year: 2000 ) . * US 2019/0298731 A1 Oct. 3 , 2019 Ricciotti et al . , Prostaglandins and Inflammation, 2011 , Arterioscler Thromb Vasc Biol . , 31 ( 5 ) , pp . 986-1000 ( Year: 2011 ) . * ( 51 ) Int .
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Figure S1. Flow Chart to Present the Experimental Design of the Present Study
    Figure S1. Flow chart to present the experimental design of the present study. Figure S2. Volcano plot showing the differentially expressed genes between papillary renal cell carcinoma and non-cancer adjacent samples. Figure S3. The 2D molecular structures of the top 10 drugs. Table SI. The 60 potential drugs for papillary renal cell carcinoma treatment based on differently expressed genes. Drug name Dose Cell line Score Instance ID Pinacidil (C13H19N5) 16 µM HL60 -1 2406 Ciclosporin (C62H111N11O12) 3 µM HL60 -0.994 1331 Naftifine (C21H21N) 12 µM HL60 -0.966 2974 Vorinostat (C14H20N2O3) 10 µM HL60 -0.961 1161 Metacycline (C22H22N2O8) 8 µM HL60 -0.943 2901 Sulfacetamide (C8H10N2O3S) 16 µM HL60 -0.939 1859 Chlorprothixene (C18H18ClNS) 11 µM HL60 -0.938 1272 Amiodarone (C25H29I2NO3) 6 µM HL60 -0.933 2434 Noretynodrel (C20H26O2) 13 µM HL60 -0.914 1860 Valproic acid (C8H16O2) 200 µM HL60 -0.91 1155 Oxolinic acid (C13H11NO5) 15 µM HL60 -0.903 1419 Monocrotaline (C16H23NO6) 12 µM PC3 -0.881 7127 LY-294002 (C19H17NO3) 10 µM HL60 -0.869 1168 Aceclofenac (C16H13Cl2NO4) 11 µM PC3 -0.863 7269 Hyoscyamine (C17H23NO3) 14 µM HL60 -0.859 1424 Heliotrine (C16H27NO5) 13 µM HL60 -0.85 2180 Trichostatin A (C17H22N2O3) 1 µM HL60 -0.85 1175 Sulfachlorpyridazine (C10H8ClN4O2S) 14 µM HL60 -0.85 2191 Diflorasone (C22H28F2O5) 8 µM HL60 -0.838 2142 Yohimbine (C21H26N2O3) 10 µM MCF7 -0.833 6777 Sulfadiazine (C10H10N4O2S) 16 µM HL60 -0.833 1852 Pargyline (C11H13N) 20 µM PC3 -0.832 2102 Haloperidol (C21H23ClFNO2) 10 µM HL60 -0.829 6203 Methazolamide (C5H8N4O3S2) 17
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • Using Saccharomyces Cerevisiae for the Biosynthesis of Tetracycline Antibiotics
    Using Saccharomyces cerevisiae for the Biosynthesis of Tetracycline Antibiotics Ehud Herbst Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2019 © 2019 Ehud Herbst All rights reserved ABSTRACT Using Saccharomyces cerevisiae for the biosynthesis of tetracycline antibiotics Ehud Herbst Developing treatments for antibiotic resistant bacterial infections is among the most urgent public health challenges worldwide. Tetracyclines are one of the most important classes of antibiotics, but like other antibiotics classes, have fallen prey to antibiotic resistance. Key small changes in the tetracycline structure can lead to major and distinct pharmaceutically essential improvements. Thus, the development of new synthetic capabilities has repeatedly been the enabling tool for powerful new tetracyclines that combatted tetracycline-resistance. Traditionally, tetracycline antibiotics were accessed through bacterial natural products or semisynthetic analogs derived from these products or their intermediates. More recently, total synthesis provided an additional route as well. Importantly however, key promising antibiotic candidates remained inaccessible through existing synthetic approaches. Heterologous biosynthesis is tackling the production of medicinally important and structurally intriguing natural products and their unnatural analogs in tractable hosts such as Saccharomyces cerevisiae. Recently, the heterologous biosynthesis of several tetracyclines was achieved in Streptomyces lividans through the expression of their respective biosynthetic pathways. In addition, the heterologous biosynthesis of fungal anhydrotetracyclines was shown in S. cerevisiae. This dissertation describes the use of Saccharomyces cerevisiae towards the biosynthesis of target tetracyclines that have promising prospects as antibiotics based on the established structure- activity relationship of tetracyclines but have been previously synthetically inaccessible.
    [Show full text]
  • Adsorption of Tetracycline by a Tailor- Made Adsorbent in Aqueous System
    Journal of Applied Biotechnology & Bioengineering Research Article Open Access Adsorption of tetracycline by a tailor- made adsorbent in aqueous system Abstract Volume 6 Issue 1 - 2019 Tetracyclines are frequently used antibiotics for growth promotion and therapeutic Adelagun Ruth Olubukola Ajoke pharmaceuticals both by humans and animal husbandry, and commonly encountered in Department of Chemical Sciences, Federal University, Nigeria municipal wastewater treatment plants and in the environment in their active form. This implies their continuous release into the environment may facilitate toxic effects both Correspondence: Adelagun Ruth Olubukola Ajoke, on humans and the environment including development of resistance strains, among Department of Chemical Sciences, Federal University, Wukari, others. This research was focused on the synthesis, characterisation and assessment Nigeria, Email of a tailor- made adsorbent: modified chitosan flakes, using several materials for the modification of chitosan to enhance its sorption properties thereby facilitating a higher Received: December 24, 2018 | Published: February 01, 2019 percentage of TC removal from a synthetic pharmaceutical wastewater. TC adsorption onto the modified chitosan flakes was relatively fast (equilibrium time = 2h). Sorption studies revealed that TC removal by the adsorbent followed pseudo second order kinetics and Freundlich isotherm models. At higher TC input concentration, the amount of TC removed was also higher, this implied the sorption was concentration dependent.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Corticosteroids ELISA
    THE PRESENT DOCUMENT IS A FAC-SIMILE VERSION When performing the assay, please use the kit insert Enzyme immunoassay for the detection of tetracyclines (code AB754/AB752) B ZERO® Tetra/Epimers is an ELISA kit prepared for an immunoenzymatic assay for the quantitative analysis of tetracyclines. 1 TEST PRINCIPLE The kit contains the procedure and the materials sufficient for The assay is performed in plastic microwells that have been 96 determinations (code AB754) or 48 determinations (code coated with anti-tetracycline antibody. Assay buffer, AB752). tetracycline zero standard solution or samples and the enzyme A microtiter plate photometer or a strip photometer is conjugate are added to the microplate. During the first required. incubation, free tetracycline molecules eventually contained in the sample and the enzyme-labelled tetracycline compete for Analysable samples the anti-tetracycline antibody binding sites on the solid phase. Muscle, honey, milk, shrimp, water. Any unbound molecule is then removed from the solid phase in a washing step. The binding between the enzyme conjugate Sample preparation and the antibody is detected by a chromogenic substrate. The (Homogenization), mixing, (centrifugation), dilution. enzyme converts the colourless chromogen into a blue product. The addition of the stop reagent leads to a colour Assay time: 90 minutes (sample preparation not included). change from blue to yellow. The absorbance is measured by a microplate reader at 450 nm. The colour development is Detection limit (in tetracycline equivalents) inversely proportional to the tetracycline concentration in the Honey, milk, shrimp: 4 ppb sample. Muscle: 8 ppb Water: 1.11 ppb 2 PROVIDED REAGENTS Specificity Microtiter plate: coated with anti-tetracycline antibody.
    [Show full text]
  • Statistical Analysis Plan / Data Specifications the Risk of Acute Liver Injury Associated with the Use of Antibiotics. a Replica
    WP6 validation on methods involving an extended audience Statistical analysis plan / data specifications The risk of acute liver injury associated with the use of antibiotics. A replication study in the Utrecht Patient Oriented Database Version: July 11, 2013 Authors: Renate Udo, Marie L De Bruin Reviewers: Work package 6 members (David Irvine, Stephany Tcherny-Lessenot) 1 1. Context The study described in this protocol is performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium). The overall objective of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. Work package 6 “validation on methods involving an extended audience” aims to test the transferability/feasibility of methods developed in other WPs (in particular WP2 and WP5) in a range of data sources owned or managed by Consortium Partners or members of the Extended Audience. The specific aims of this study within WP6 are: to evaluate the external validity of the study protocol on the risk of acute liver injury associated with the use of antibiotics by replicating the study protocol in another database, to study the impact of case validation on the effect estimate for the association between antibiotic exposure and acute liver injury. Of the selected drug-adverse event pairs selected in PROTECT, this study will concentrate on the association between antibiotic use and acute liver injury. On this topic, two sub-studies are performed: a descriptive/outcome validation study and an association study. The descriptive/outcome validation study has been conducted within the Utrecht Patient Oriented Database (UPOD).
    [Show full text]